Last Updated : January 26, 2023
Details
FilesGeneric Name:
cabozantinib
Project Status:
Complete
Therapeutic Area:
Differentiated thyroid carcinoma
Manufacturer:
Ipsen Biopharmaceuticals Canada Inc.
Brand Name:
Cabometyx
Project Line:
Reimbursement Review
Project Number:
PC0287-000
Tumour Type:
Head and Neck
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Treatment of adult and adolescent patients 12 years of age and older with differentiated thyroid carcinoma (DTC) that has progressed following prior therapy and who are radioactive iodine-refractory or ineligible.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Head and Neck
Indications:
Treatment of adult and adolescent patients 12 years of age and older with differentiated thyroid carcinoma (DTC) that has progressed following prior therapy and who are radioactive iodine-refractory or ineligible.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones |
|
|---|---|
| Call for patient/clinician input open | March 29, 2022 |
| Call for patient/clinician input closed | May 20, 2022 |
| Clarification:
- Patient input submission received from Canadian Cancer Society and Thyroid Cancer Canada |
|
| Submission received | April 27, 2022 |
| Submission accepted | May 11, 2022 |
| Review initiated | May 12, 2022 |
| Draft CADTH review report(s) provided to sponsor for comment | July 27, 2022 |
| Deadline for sponsors comments | August 08, 2022 |
| CADTH review report(s) and responses to comments provided to sponsor | September 01, 2022 |
| Expert committee meeting (initial) | September 14, 2022 |
| Draft recommendation issued to sponsor | September 28, 2022 |
| Draft recommendation posted for stakeholder feedback | October 06, 2022 |
| End of feedback period | October 21, 2022 |
| Final recommendation issued to sponsor and drug plans | November 02, 2022 |
| Final recommendation posted | November 17, 2022 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | November 22, 2022 |
| CADTH review report(s) posted | January 24, 2023 |
Files
Last Updated : January 26, 2023